BlinkLab Secures A$17.5M to Fund the Launch of Autism Diagnostic Aid and Expand ADHD Program

Highlights:

• BlinkLab has successfully completed an oversubscribed Placement of New Shares to domestic and international Institutional and Sophisticated investors.
• Firm commitments secured for A$17.5 million (before costs), at A$0.65 per ordinary share.
• BlinkLab’s full Board and Management have participated in the raise and committed to contribute A$200K as part of the Placement (Directors’ portions subject to shareholder approval).
• Funds raised from the Placement will be used to:
  
  • Support the completion of the ongoing FDA 510(k) registrational trial for autism diagnosis using BlinkLab’s Dx1 platform.
  • Support CE and MDR approval processes for BlinkLab Dx1 in Europe, the Company’s diagnostic tool for autism.
  • Launch a second clinical programme in the U.S. using the Company’s BlinkLabDx2 platform as a diagnostic aid for ADHD.
  • Initiate the FDA 510(k) registrational trial process for use of BlinkLab Dx2 to detect ADHD.
  • Provide additional working capital to support BlinkLab’s ongoing operations, platform development, and extend the Company’s patent portfolio.
  • Morgans Corporate, Westar Capital and Alpine Capital acted as Joint Lead Managers for the Placement.

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), a leading digital healthcare company focused on the development of AI-powered diagnostic technology, is pleased to announce that it has successfully completed an oversubscribed Placement (the “Placement”) of ordinary shares (“NewShares”) to sophisticated and institutional investors; raising a total of A$17.5 million (before costs) at a price of A$0.65 per ordinary share. The successful completion of the Placement represents a critical milestone for BlinkLab as the Company advances toward regulatory approval and commercialisation of its lead product, BlinkLab Dx1, a diagnostic aid for the detection of autism.

Use of Placement Funds

Proceeds from the Placement will directly support the execution of the Company’s pivotal U.S. FDA510(k) regulatory trial for clearance as an aid in the diagnostic process for autism; a key inflection point that underpins BlinkLab’s pathway to becoming a clinically validated, scalable diagnostic platform in one of the largest and most underserved areas in paediatric healthcare. In parallel, funds will accelerate the Company’s European regulatory strategy, including CE marking and compliance with EU Medical Device Regulation (MDR) requirements, positioning the BlinkLab Dx1 platform for access across major international markets. In addition, a portion of the proceeds will be allocated to advancing the Company’s U.S.-focused ADHD program, including the initiation of clinical studies to expand BlinkLab’s platform into this significantly larger and complementary market opportunity.

BlinkLab Dx1 (Autism) – Approaching Commercial Readiness

This funding will accelerate the transition of BlinkLab’s Dx1 technology platform from clinical validation into late-stage regulatory and commercial readiness. With strong pilot data already exceeding FDA agreed performance thresholds for BlinkLab Dx1,¹ the Company is now focused on delivering robust, real-world evidence through its registrational program, while simultaneously building the operational, regulatory and market access foundations required for commercial launch in the United States. This dual-track strategy significantly enhances the Company’s ability to capture early mover advantage in a market that is increasingly demanding objective, scalable, and technology-driven diagnostic solutions.

BlinkLab Dx2 (ADHD) – Parallel FDA Regulatory Pathway

Beyond autism, the Placement also enables BlinkLab to expand its platform into adjacent, high-value indications, most notably ADHD, where the Company expects to initiate U.S. clinical studies in the near term. ADHD represents a substantially larger patient population, and the ability to leverage the same smartphone-based platform and AI-driven infrastructure creates a compelling opportunity to extend BlinkLab’s diagnostic suite with minimal incremental cost. This positions the Company to address a broader spectrum of neurodevelopmental conditions, reinforcing its ambition to become a leading digital diagnostics platform.

The importance of this capital raise is further underscored by the strong thematic tailwinds supporting the sector. Autism and related neurodevelopmental disorders remain significantly underdiagnosed and subject to long waiting times, creating a clear and urgent unmet clinical need. At the same time, regulators, clinicians, and industry are increasingly embracing artificial intelligence and digital biomarkers as tools to improve diagnostic accuracy, accessibility, and scalability. BlinkLab sits at the intersection of these trends, and this funding provides the resources required to capitalise on a rapidly evolving landscape where new technologies are poised to redefine how neurodevelopmental conditions are identified and managed.

Commenting on the Placement, BlinkLab’s Co-founder, Managing Director & CEO, Dr Henk- JanBoele, stated:

“This capital raise is another major milestone for BlinkLab. It is a direct result of the incredible dedication shown by our team and our clinical partners. They have worked tirelessly for several years to advance this technology to its current stage, from developing the foundational science to successfully executing complex clinical studies within the promised timelines, a particularly challenging feat in the medtech and clinical trial environment. It has required an extraordinary level of commitment to ensure we deliver a robust software product that meets the highest clinical and regulatory standards.

As a medical doctor, I have seen first-hand the challenges families face in navigating the diagnostic journey for autism and other neurodevelopmental conditions. Long waiting times, subjective assessments, and variability in access to specialists create a significant burden on both patients and healthcare systems. BlinkLab Dx1 has been designed to directly address this unmet need by providing an objective, accessible, and scalable diagnostic tool that can support earlier identification and intervention.

With this funding, we are now well positioned to complete our pivotal U.S. study and progress toward FDA approval, while also advancing our European regulatory strategy. Importantly, it also enables us to expand into ADHD, where the need for better diagnostic tools is arguably even greater. We believe this is just the beginning of what our platform can achieve in transforming the way neurodevelopmental conditions are diagnosed and managed.

We extend our sincere gratitude to our investors and the excellent work by our Joint LeadManagers in this capital raise. Funding will enable BlinkLab to continue our exciting journey and deliver our milestones on schedule.”

Also commenting on the Placement, BlinkLab’s Chairman, Mr Brian Leedman, stated:

“We are very pleased with the strong support received for this placement, particularly from high-quality institutional investors who share our long-term vision. At this stage of theCompany’s development, it is critical to build a register that is aligned with our strategy, especially as we prepare to enter the United States, the largest and most important healthcare market globally.

This capital raise not only strengthens our balance sheet but also establishes relationships with investors who understand the scale of the opportunity ahead and the significance of whatBlinkLab is seeking to achieve. As we move closer to regulatory approval and commercialisation, having the right partners on the register becomes increasingly important.

We believe BlinkLab is entering a highly attractive phase of growth, supported by strong clinical progress, a clear regulatory pathway, and powerful sector tailwinds in digital health and AI-driven diagnostics. The Board looks forward to executing on this next stage and delivering longterm value for shareholders.”

Placement Details

Through the Placement to a range of domestic and international institutional and sophisticated investors, BlinkLab has received firm commitments to raise A$17.5 million (before costs) at A$0.65 per ordinary share.

Pursuant to the Placement, BlinkLab proposes to issue 26,923,077 new fully-paid ordinary shares in the Company (New Shares), at an issue price of A$0.65 per new share. This represents a 17.2% discount from the last traded price of BlinkLab shares on 13 April 2026, and a 15.3% discount to the 15-day VWAP prior to the last trading date.

A total of 14,656,983 New Shares will be issued using the Company’s 15% placement capacity under Listing Rule 7.1, and 12,000,000 New Shares within the Company’s additional 10% placement capacity under Listing Rule 7.1A.

The New Shares utilising the Company’s combined 7.1 and 7.1A placement capacity are expected to be issued on Thursday 23 April 2026.

The proposed issue of 266,094 New Shares to directors is subject to shareholder approval. The Company will convene a general meeting (GM) seeking approval for the New Shares to Directors as soon as possible (mid-June 2025). Additionally, management has applied for 41,598 New Shares (combined with the Directors totalling $200k).

Any New Shares issued under the Placement will be fully paid ordinary shares in the Company and will rank equally with shares currently on issue.

Morgans Corporate Limited, Westar Capital Ltd & Alpine Capital Pty Ltd acted as Joint Lead Managers to the Placement (JLM). The JLM will receive 7% of gross funds raised under the Placement and one option (New Option) for every 5 New Shares issued under the Placement, with an exercise price of A$0.975 per New Option and expiry of 30 June 2028. Cash fees and New Options will be split equally between each of the JLM. The issue of New Options to the JLM is subject to shareholder approval at the GM of shareholders proposed for mid-June 2026.

About BlinkLab Dx1 & BlinkLab Dx2

BlinkLab Limited’s initial diagnostic technology, BlinkLab Dx1, is a diagnostic aid aimed at supporting clinicians in identifying autism. This smartphone-based neurological assessment is designed to provide rapid, accessible, and accurate autism screening, helping healthcare providers to intervene earlier and more efficiently, therefore, achieving better patient outcomes through earlier intervention.

With the initial successes demonstrated by BlinkLab Dx1 for autism, the Company is currently developing BlinkLab Dx2, a diagnostic adjunct that uses the exact same smartphone-tech, app and online portal, but slightly different digital biomarkers generated by a child’s interaction with the smartphone app that help to evaluate brain function and detect possible indicators of ADHD.

This announcement is intended to lift the Company’s trading halt.

This announcement has been approved by the Board of Directors.

Footnotes

1. ASX Announcement (22 October 2025) – “Pilot Study Confirms High Diagnostic Accuracy and Readiness for FDA Trial"